Ongoing partial response at 6 months to olaparib for metastatic melanoma with somatic PALB2 mutation after failure of immunotherapy: a case report

Ann Oncol. 2021 Feb;32(2):280-282. doi: 10.1016/j.annonc.2020.11.006. Epub 2020 Dec 9.

Authors

B Lau¹, A M Menzies², A M Joshua³

Affiliations

¹ Kinghorn Cancer Centre, Department of Medical Oncology, St Vincent's Hospital Sydney and Garvan Institute of Medical Research, Sydney, Australia.
² Melanoma Institute of Australia, Sydney, Australia.
³ Kinghorn Cancer Centre, Department of Medical Oncology, St Vincent's Hospital Sydney and Garvan Institute of Medical Research, Sydney, Australia; Melanoma Institute of Australia, Sydney, Australia. Electronic address: anthony.joshua@svha.org.au.

PMID: 33308898
DOI: 10.1016/j.annonc.2020.11.006

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Fanconi Anemia Complementation Group N Protein
Humans
Immunotherapy
Melanoma* / drug therapy
Melanoma* / genetics
Mutation
Phthalazines* / therapeutic use
Piperazines

Substances

Fanconi Anemia Complementation Group N Protein
PALB2 protein, human
Phthalazines
Piperazines
olaparib